ReviewBMC pulmonary medicine2025
Post-steroid rebound in COVID-19 pneumonitis: a case series and review of the literature.
Review in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a retrospective case series of COVID-19 pneumonitis (C19P) patients in hypoxic respiratory failure who experienced a symptom rebound upon cessation or weaning of steroids following an initial positive response. The post-steroid rebound phenomenon in C19P is not well described in the literature and we aim to add to the body of evidence exploring this pathology.
methodsPost-steroid rebound COVID-19 pneumonitis (PSRCP) cases at our institution were identified for notes review from respiratory department follow-up records. The inclusion criteria were as follows: 1. Hospital admissions with radiologically and PCR-confirmed C19P. 2. Administration of a corticosteroid course for the indication of hypoxia due to C19P. 3. An objective relapse of the index presentation with differential diagnoses other than post-steroid rebound excluded by appropriate clinicians. A literature search was performed using Medline, Ovid and Google Scholar and the search terms "rebound and COVID-19", "rebound and COVID-19 and pneumonitis" "post-COVID and pneumonitis" "relapse and COVID-19", "relapse and coronavirus and pneumonitis".
resultsEighteen patients were identified between 2021 and 2024 with ages ranging from 48 to 80 years. The most common comorbidities were hypertension (50%) and obesity (39%) while 89% had a history of regular smoking. Seventeen of the 18 had evidence of hyperinflammation at first C19P presentation with a C-reactive protein (CRP) ≥ 75 mg/dl. Notably, 15 patients had a CRP blood test at least 48 h prior to discharge, steroid cessation or weaning and of these, 11 (73%) showed persisting CRP elevation. Seventeen of the 18 responded upon diagnosis of PSRCP to steroid rechallenge with survival to discharge.
conclusionsAs COVID-19 becomes endemic, clinicians should remain wary of the risk of PSRCP. Greater recognition of the importance of steroid weans and rechallenges in C19P narratives will help avoid poor outcomes, readmissions and the risk of post-C19P sequelae. Awareness of the PSRCP phenomenon should lower the threshold for slow steroid weans upon an initial C19P diagnosis over the standard UK regimen of a 10-day duration or less dexamethasone course. A definition for PSRCP is proposed as well as a decision aid around steroid strategies in patients both with and at risk of PSRCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.